Deep venous stents
Abre™ venous self-expanding stent system
The Abre™ venous self-expanding stent system is designed for the unique challenges of venous disease.
Explore the Abre™ venous stent system.
Simplicity for you.
Durability for them.
Watch the Abre™ stent mechanism of action.
Indications
The Abre™ stent system is intended for use in the iliofemoral veins for the treatment of symptomatic venous outflow obstruction.
Clinical evidence
Clinically meaningful impact on quality of life through 36 months — in even the most complex patients.
36-month primary patency†,1:
- 81.6% overall
- 97.1% NIVL
- 76.5% aDVT
- 70.4% PTS
Product details
Simplicity for you1,2
Hear it from the expert.
Durability for them1,2
Hear it from the expert.
Easy deployment to let you focus on your patient1,2
The Abre™ stent minimizes jumping and foreshortening, landing precisely where you need it.2
Rotating thumbwheel offers predictable placement and auditory feedback.2
- Isolation sheath
- Hemostatic valve
- Introducer sheath
- Retractable sheath
- Inner shaft
Demonstrated endurance to give your patients freedom of movement1,2
The nitinol Abre™ stent maintains lumen integrity and flow in diverse patients and anatomies.1 It ensures radial strength and crush resistance, without compromising flexibility.2
Unique technology:
- Open-cell design with three offset connection points
- Struts customized to each size
Consistent behavior across a broad range of diameters and lengths.2
Bench evidence shows long-term durability.2 Clinical evidence shows real-world dependability, even in challenging cases.1
- 0% fracture rate in clinical trial with 44% of stents extending below inguinal ligament into the common femoral vein (CFV)‡,1
- 0% migration rate in clinical trial1
Ordering information
Item number guide

| Stent diameter (mm) | Stent length (mm) | |||||
|---|---|---|---|---|---|---|
| 40 | 60 | 80 | 100 | 120 | 150 | |
| 10 | AB9G10040090 | AB9G10060090 | AB9G10080090 | AB9G10100090 | AB9G10120090 | AB9G10150090 |
| 12 | — | AB9G12060090 | AB9G12080090 | AB9G12100090 | AB9G12120090 | AB9G12150090 |
| 14 | — | AB9G14060090 | AB9G14080090 | AB9G14100090 | AB9G14120090 | AB9G14150090 |
| 16 | — | AB9G16060090 | AB9G16080090 | AB9G16100090 | AB9G16120090 | AB9G16150090 |
| 18 | — | AB9G18060090 | AB9G18080090 | AB9G18100090 | AB9G18120090 | AB9G18150090 |
| 20 | — | AB9G20060090 | AB9G20080090 | AB9G20100090 | AB9G20120090 | AB9G20150090 |
Related links
† Primary patency was defined as meeting all of the following: freedom from occlusion or restenosis ≥ 50% of the stented segment of the target lesion and freedom from clinically driven target lesion revascularization.
‡ Stent fracture and stent location was assessed by imaging core labs. Site reported data was used when core lab data was not available.
§ TLR was defined as any reintervention of the stented segment of the target lesion.
- Abre™ venous stent instructions for use.
- Test data on file at Medtronic. Report 10558227DOC_Rev A. Bench test results may not be indicative of clinical performance.
- Vogel J, Cheng C, Murphy E, Black S, Desai K. Fatigue test method to evaluate the 50 year durability of venous stents. Eur J Vasc Endovasc Surg. 2024;68(4):521–528. doi:10.1016/j.ejvs.2024.06.024.